Parasetamol
PreclinicalSmall molecule
Parasetamol is one of 42 small molecule programs targeting Hysterectomy. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
49 competitors in Hysterectomy
#DrugCompanyPhaseTrials
1Toradol
RocheApproved
Golytely
BayerApproved
Medrol
PfizerApproved
Atarax
PfizerApproved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Marcaine
IInnocoll
Approved
Oxycontin
PProtega
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Neurontin
VViatris Specialty LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Parasetamol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- GGiresun University